Second-line therapeutic options in non-small-cell lung cancer

Lung Cancer

Volumn 54, Issue SUPPL. 2, 2006, Pages

  Vansteenkiste, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Docetaxel; Erlotinib; NSCLC; Pemetrexed; Second line; Sequence

Indexed keywords

DOCETAXEL; ERLOTINIB; GEFITINIB; IFOSFAMIDE; NAVELBINE; PEMETREXED;

ALOPECIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; EVIDENCE BASED MEDICINE; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RASH;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TREATMENT OUTCOME;

EID: 33750633035     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.09.019     Document Type: Article

References (22)

1. Fossella F.V., Lee J.S., and Hong W.K. Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24 (1997) 455-462
2. Burris H., Eckhardt J., Fields S., Rodriguez G., Smith L., Thurman A., et al. Phase II trial of Taxotere with non-small cell lung cancer. Proc Am Soc Clin Oncol 12 (1993) 335 [abstract 1116]
3. Fossella F.V., Lee J.S., Shin D.M., Calayag M., Huber M., Perez-Soler R., et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13 (1995) 645-651
4. Gandara D.R., Vokes E., Green M., Bonomi P., Devore R., Comis R., et al. Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer: a confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol 16 (1997) 454a [abstract 1632]
5. Robinet G., Kleisbaurer J.P., Thomas P., Perol M., Balmes P., Vernejoux J.M., et al. Phase II study of Taxotere (docetaxel) in advanced or metastatic non-small cell lung cancer previously treated with platinum. Ann Oncol 7 5S (1996) 96-97 [abstract 458P]
6. Robinet G., Kleisbaurer J.P., Thomas P., Perol M., Carles P., Paillotin D., et al. Phase II study of docetaxel (Taxotere) in first- and second-line NSCLC. Proc Am Soc Clin Oncol 16 (1997) 480a [abstract 1726]
7. ®) in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 7 5S (1996) 429a
8. Le Chevalier T. Docetaxel: meeting the challenge of non-small cell lung cancer management. Anticancer Drugs 6 S4 (1995) 13-17
9. Yokoyama A., Kurita Y., and Watanabe K. Early Phase II clinical study of RP56976 (docetaxel) in patients with primary pulmonary cancer: docetaxel Cooperative Study Group for Lung Cancer. Gan To Kagaku Ryoho 21 (1994) 2609-2616
10. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
11. Fossella F.V., DeVore R., Kerr R.N., Crawford J., Natale R.R., Dunphy F., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18 (2000) 2354-2362
12. Rollins K.D., and Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 27 (2005) 1343-1382
13. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
14. Pujol J.L., Paul S., Gatzemeier U., Kayitalire L., and Berry D. Risk-benefit of pemetrexed compared with docetaxel in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy: an analysis of toxicity-free survival. Ann Oncol 15S (2004) 186
15. Bunn P., Rosell R., Fossella F., Perry M., Stahel R., Barata F., et al. An exploratory analysis of a phase III study in patients with advanced non-small cell lung cancer (NSCLC): the impact of first-line gemcitabine and platinum therapy on the outcome of second-line therapy with pemetrexed or docetaxel. Lung Cancer 49 S2 (2005) 86S [abstract]
16. Huang S.M., and Harari P.M. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 17 (1999) 259-269
17. Rusch V., Klimstra D., Venkatraman E., Pisters P.W., Langenfeld J., and Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3 (1997) 515-522
18. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 21 (2003) 2237-2246
19. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
20. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 (2004) 3238-3247
21. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
22. Tsao M.S., Sakurada A., Cutz J.C., Zhu C.Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144